A surface immunofluorescence assay (SIFA) was analyzed and compared with a conventional indirect immunofluorescence assay (IFA) and whole-cell enzyme-linked immunosorbent assay (ELISA) for detecting immunoglobulin G (IgG) antibodies to Borrelia burgdorferi in sera from patients with Lyme disease. Fifty-five patients with syphilis and 33 patients with rheumatoid arthritis were used as disease controls. The sensitivity of the SIFA was low during the acute phase of Lyme disease (sera from seven of nine patients presenting with erythema chronicum migrans were negative during the first 2 months of illness); later, seroconversion was observed in all patients at various times during convalescence. Sera from five patients with complicated Lyme disease were strongly positive. SIFA was found to be highly specific, since sera from all patients with secondary or latent syphilis and patients with rheumatoid arthritis did not react in the test. Strong cross-reactivity occurred when these sera were tested in conventional IFA and ELISA; sera from 38 (69%) patients with syphilis were positive by WFA and sera from 51 (93%) patients were positive by ELISA, whereas 7 (21%) and 12 (36%) of the serum samples from patients with rheumatoid arthritis were positive by IFA and ELISA, respectively. Immunoblot analysis of SIFA-positive sera showed that the 31-and 34-kDa outer surface proteins (proteins A and B, respectively) of B. burgdorferi were the major reactive antigens involved in the test. The results support a role for SIFA in the investigation of complicated Lyme disease as well as in the differentiation of Lyme disease from other diseases associated with B. burgdorferi cross-reactive antibodies.
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Lyme disease is a tick-transmitted infection caused by the spirochete Borrelia burgdorferi (9) . The diagnosis of Lyme disease is mainly clinical. However, when clinical records are incomplete, serological tests may be required to identify the cause of infection, since Lyme borreliosis shares many symptoms and signs with other established diseases (31) . Indirect immunofluorescence assay (IFA) staining of whole Borrelia cells and enzyme-linked immunosorbent assay (ELISA) are used to detect antibodies to B. burgdorferi (28) . However, false-positive reactions are well documented in the serodiagnosis of Lyme disease (24) , at least in part because of the cross-reactive antigens that are present on the flagella of B. burgdorferi, other Borrelia spp., and Treponema spp (1) . A 60-kDa antigen of B. burgdorferi is also believed to be the common antigen which has cross-reactive epitopes with analogous antigens produced by many other bacteria (17) . In addition, serological tests for Lyme borreliosis also have been shown to be inadequate in separating Lyme borreliosis from rheumatoid arthritis (21) .
To improve the specificity of diagnostic tests for Lyme disease, whole B. burgdorferi cells have been replaced either with fractions of spirochetes in the ELISA (23) or the sera have been previously absorbed with heterologous crossreactive antigens in the IFA (25) . In this study we evaluated the possibility of using immunoglobulin G (IgG) antibodies directed against the surface antigens of living B. burgdorferi cells in a surface immunofluorescence assay (SIFA) for the diagnosis of Lyme disease. * Corresponding author.
MATERIALS AND METHODS
Study groups. Serum samples were obtained from subjects who were clinically and serologically diagnosed as having Lyme borreliosis (n = 14) or syphilis (n = 55). In addition, 33 serum samples from patients with rheumatoid arthritis were studied.
Lyme disease patients. Nine patients had a history of tick bite and erythema chronicum migrans (ECM), whereas five patients presented with one of the late manifestations of the disease: arthritis (four patients) and neuritis (one patient). A serum sample was obtained from the patients at the time of clinical diagnosis. Serum samples were similarly obtained after 2 to 3 and 6 to 12 months. Two additional serum samples were collected from two patients. All patients gave informed consent for the serial bleedings. All patients received antibiotic therapy. The duration of oral administration of doxycycline or amoxicillin was usually up to 3 weeks for patients with ECM and 1 month for patients with Lyme arthritis. Treatment for neuritis was with ceftriaxone given intravenously for 4 weeks.
Bacterial strains and culture conditions. B. burgdorferi IRS and B. hennsii HS-1 were originally obtained from M. A. Lovett, University of California, Los Angeles. Borreliae were maintained in Barbour-Stoenner-Kelly (BSK-II) medium (2) at 34WC in a standard air incubator and were subcultured every 5 days, as described previously (12 EFA. In the conventional IFA, the spirochetes were grown in BSK-II medium for 5 to 7 days, and the cells were harvested by centrifugation (8,200 x g) for 30 min. The organisms were washed in phosphate-buffered saline (PBS) two times and diluted to approximately 200 bacteria per dry high-power field (magnification, x400). A total of 10 to 20 pl of the suspensions was added to each well of microscope slides, air dried, and fixed in acetone for 5 min. Serial twofold dilutions of test sera or mouse immune ascites were made in PBS. A total of 10 to 15 RI of each dilution was placed onto each antigen-coated well, and the slides were incubated in a humidified chamber at 37°C for 30 min and were then washed three times in PBS. Fluorescein-conjugated rabbit anti-human IgG or anti-mouse immunoglobulins diluted 1:30 in PBS were then added, as above described. A commercially available IFA (DMD, Gailingen, Germany) was used to validate our in-house procedure. The results were absolutely comparable as far as the 1:2 dilution.
ELISA. Sonicated whole spirochetes were prepared by the method of Craft et al. (14) . Briefly, B. burgdorfen IRS grown in BSK-II medium for 5 to 7 days was centrifuged at 10,000 x g for 20 min, washed with PBS, and then sonicated on ice. The indirect ELISA was done by standard methods as described previously (10) . Ninety-six-well microtitration plates (Dynatech Laboratories, Guernsey, United Kingdom) were coated with 200 ,ul of a 0.015-mg/ml solution of spirochetal protein. After washing, 200-,u aliquots of serum samples diluted 1:200 were added to the wells in triplicate; this was followed by incubation with peroxidase-conjugated rabbit antibody to human IgG (Dako) diluted 1:500. Thereafter, 100 pi of citric acid-phosphate buffer (pH 5.6) containing 40 mg of 1,2-phenylendiamine dihydrochloride (Merck, Darmstadt, Germany) was added to each well. The enzymatic reaction was stopped after 15 min by adding 100 pul of of the absorbances of sera from 245 subjects who had no known history of Lyme disease.
Production of mouse polyclonal antibodies. Mouse immune ascitic fluid containing polyclonal antibodies was obtained by immunizing BALB/c mice with B. hermsii HS-1 or B.
burgdorfen IRS whole cells by a previously described technique (13) . Briefly, 0.8-ml volumes of immunogen (0.05 mg of protein) emulsified 1:9 (vol/vol) with complete Freund's adjuvant were injected intraperitoneally into 8-to 12-weekold mice on days 0, 7, 14, and 21. On day 6, 0.5 ml of pristane (2, 6 ,10,14-tetramethylpentadecane; Sigma, St. Louis, Mo.) was injected intraperitoneally. Mice were monitored daily for the appearance of ascites. Ascitic fluid samples were collected on day 30 by peritoneal paracentesis by using a sterile 21-gauge needle.
SDS-PAGE and Western immunoblotting. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed by the method of Laemmli (20) by using a 12.5% acrylamide gel as described previously (11) . The Western blot (immunoblot) procedure of Towbin et al. (33) was performed as described previously (11) . Briefly, after electrophoretic transfer, the blots were incubated for 12 h at room temperature with human sera or mouse immune ascites diluted 1:100 and 1:1,000, respectively, in PBS containing 0.05% (vol/vol) Tween 20. Antigen-antibody complexes were detected with peroxidase-labeled rabbit antiserum against human IgG or mouse immunoglobulins (DAKO, Copenhagen, Denmark) diluted 1:500 in PBS and by using 40 mg of benzidine (Fluka, Buchs, Switzerland) dissolved in 4 ml of acetone-96 ml of PBS-100 ,ul of hydrogen peroxide from a 33% stock solution as the enzyme substrate.
FTA-ABS. The fluorescent treponemal antibody absorption test (FTA-ABS) was performed with a commercial kit in accordance with the manufacturer's directions (Behring AG, Marburg/Lahn, Germany). FTA-ABS was done with multiwell Treponema pallidum antigen substrate slide. For specific staining by conjugates, controls were the reference diluents of Behring-phosphate buffer alone and sorbent (standardized extract of Treponema phagedenis biotype Reiter) alone, which gave no distinct fluorescence, and the following control specimens (the expected relative fluorescences are given in parentheses): reactive control diluted 1:5 with PBS (4+), reactive control diluted 1:5 with sorbent (3+), a specific positive control diluted with PBS (2+) and with sorbent (-). Test specimens were diluted 1:5 in sorbent before incubation with antigen on the slide.
RESULTS
Preliminary observations from our laboratory showed that immune ascitic fluids from mice immunized with whole B. hermsii cells were negative when tested by surface immunofluorescence with living B. burgdorfeni spirochetes, whereas the same samples were highly positive (titers range, 2,048 to 4,096) when tested by conventional IFA, as was expected. Immunoblot analysis (Fig. 1 ) of immune ascites showed that the cross-reactive antigens in the IFA were the 39-kDa protein of B. hermsii (32) , the 41-kDa protein of B. burgdorferi (3), and a 60-kDa antigen (17) which are known to be not surface exposed (30) . These results prompted us to evaluate whether the SIFA performed with living B. burgdorfen cells could detect antibody against only species-specific epitopes when sera from patients with Lyme disease and controls were tested. Antibody levels detected by IFA, ELISA, and SIFA in sera from 14 patients with Lyme disease are VOL. 30 (Fig. 2) was negative, with only two exceptions, for sera obtained during the acute phase of the disease (i.e., during the ECM stage) and often for sera obtained during the following 3-to 6-month period; after that, SIFA became positive for sera from all patients with ECM. Sera from patients who entered the study with a diagnosis of Lyme arthritis or neuritis were positive throughout the study period, showing stable high titers.
To evaluate the specificity of the test, sera from 55 patients with secondary or latent syphilis that were reactive in the FTA-ABS (19 Western blotting analysis showed that sera from patients with Lyme disease became strongly positive by SIFA when antibodies against the 31-kDa protein and, often, the 34-kDa protein were detectable. Antibodies against few other proteins with molecular masses that varied between 14 and 22 kDa were sometimes detectable (Fig. 3) . On the contrary, sera from patients with syphilis or rheumatoid arthritis that were reactive with B. burgdorferi antigens by IFA or ELISA did not recognize the 31-or 34-kDa proteins ( Fig. 3D and E) .
DISCUSSION
So far, the criteria for the diagnosis of Lyme borreliosis have not been clearly defined and may depend on subjective clinical evaluations and unreliable laboratory tests. This is because Lyme disease tends to mimic several immune disorders and inflammatory diseases. Therefore, there is a demand for improved serological tests for diagnosis of the disease. IFA (28), whole-cell ELISA (7, 14, 28) , and immunoblotting (16) have been used as serological tests for the diagnosis of Lyme borreliosis. ELISA has been also performed with B. burgdorferi cellular fractions (18, 23) , and IFA has been performed with preabsorption of sera, owing to problems of cross-reactivity, since B. burgdorfen shares common antigens with borreliae that cause relapsing fever (22, 24) and with treponemal components (22, (24) (25) (26) (27) , including flagellin. Aside from flagellin, there are additional pro- teins of B. burgdorfiei that are common to other bacteria (17) . In this study, the sensitivity of the SIFA determined in patients with clinically and serologically diagnosed Lyme disease was shown to be low during the acute phase of the illness, since 78% of serum samples from patients with ECM were negative during the first 2 months of illness. However, all patients seroconverted during the convalescent phase (3 to 12 months from the time of disease onset). Serum samples from patients with complicated Lyme disease presenting with arthritis or neuritis were always positive.
The specificity of the SIFA was also analyzed by using sera from patients with syphilis (14, 22, 24, 26, 27) or rheumatoid arthritis (21) , since these sera are known to be highly (syphilis) or moderately (rheumatoid arthritis) crossreactive in the conventional IFA and ELISA for B. burgdorferi. The (4, 6, 8, 15) .
In summary, the results indicate that SIFA, because of its specificity, may be useful in the serodiagnosis of complicated Lyme disease and helps to confirm an infection when B. burgdorferi cross-reactive antibodies are present in sera from patients with other diseases.
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